Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload

Lignende værker

• Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
  af: Taher, Ali T., et al.
  Udgivet: (2013)
• Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias
  af: Porter, John B, et al.
  Udgivet: (2011)
• Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients
  af: Taher, Ali T, et al.
  Udgivet: (2013)
• Iron overload across the spectrum of non‐transfusion‐dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions
  af: Porter, John B., et al.
  Udgivet: (2016)
• Update on the use of deferasirox in the management of iron overload
  af: Taher, Ali, et al.
  Udgivet: (2009)